Key result
Repeat genetic testing with novel methods identifies a pathogenic PKP2 variant in gene-elusive arrhythmogenic cardiomyopathy.
Why the study?
Arrhythmogenic cardiomyopathy is largely genetic, but endurance exercise disproportionately triggers gene-elusive disease, highlighting the role of periodic genetic re-evaluation.
Does periodic genetic retesting using novel analytical methods identify pathogenic variants in patients with initially gene-elusive arrhythmogenic cardiomyopathy?
Case Report (n=1)
Does periodic genetic retesting using novel analytical methods identify pathogenic variants in patients with initially gene-elusive arrhythmogenic cardiomyopathy?
Periodic genetic retesting using novel analytical methods is crucial for identifying pathogenic variants in patients with initially gene-elusive arrhythmogenic cardiomyopathy, which impacts family screening and risk stratification.
Answers are grounded in this paper and cite their sources.
Supports ACM evaluation in gene-elusive endurance athletes with CAD and RV abnormalities; leaves open need for prospective validation.
BACKGROUND: Arrhythmogenic cardiomyopathy (ACM) is predominantly a genetic disease. Endurance exercise acts as a disproportionate trigger in gene-elusive ACM. CASE SUMMARY: A 52-year-old male endurance athlete with stable coronary artery disease and no family history of ACM presented with premature ventricular contractions, right ventricular dilatation, and subtricuspid dyskinesia. After multimodality evaluation, "borderline" biventricular ACM was diagnosed. Genetic testing was negative, leading to a working diagnosis of exercise-induced ACM. Repeat genetic testing after 3 years using novel analytical methods identified a deep intronic pathogenic variant of PKP2. DISCUSSION: The identification of a pathogenic variant is relevant for family screening, risk stratification, and exercise counseling because most available outcome data apply to desmosomal ACM. Periodic genetic retesting is advised in gene-elusive ACM. TAKE-HOME MESSAGES: Periodic genetic retesting and readjudication is crucial for the management of gene-elusive ACM. Robust evidence-based data to guide personalized exercise recommendations in ACM are lacking.
No takes yet. Share an insight, caveat, or question.
Tramer et al. (2026) conducted a case report in Arrhythmogenic cardiomyopathy (n=1). Repeat genetic testing vs. Initial genetic testing was evaluated on Identification of pathogenic variant. Repeat genetic testing using novel analytical methods after 3 years in a 52-year-old male athlete with gene-elusive arrhythmogenic cardiomyopathy identified a deep intronic pathogenic variant of PKP2.
Synapse has enriched 10 related papers. Consider them for comparative context: